CAR-T Cell Therapy for Autoimmune Diseases: What the Early Data Shows

WHAT THIS ARTICLE COVERS

CAR-T cell therapy, engineered to hunt down cancerous B cells, is now being tested in a very different setting: severe, treatment-resistant autoimmune diseases like lupus, myositis, and systemic sclerosis. Early case series and a growing basket trial out of Germany have reported something rheumatologists rarely see — sustained, drug-free remission in patients who had run out of options. This article walks through why researchers thought CAR-T might work here, what the actual published data shows, which companies are furthest along, and the substantial risks and unknowns that stand between these encouraging early results and any approved treatment.

WHY RESEARCHERS TRIED THIS

Diseases like systemic lupus erythematosus (SLE), inflammatory myositis, and systemic sclerosis are driven, in part, by B cells that produce autoantibodies attacking the body's own tissue. Standard treatments — steroids, immunosuppressants, biologics like rituximab or belimumab — dampen this activity but rarely eliminate it, and many patients cycle through drug after drug while organ damage accumulates. CD19-targeted CAR-T cells, originally built to eradicate B-cell leukemias and lymphomas, don't just suppress B cells the way antibody drugs do — they physically hunt and destroy them, including in tissue compartments like lymph nodes and bone marrow that antibody-based B-cell depletion doesn't reach as thoroughly. The theory, advanced most prominently by rheumatologist Georg Schett's group at University Hospital Erlangen in Germany, is that a deep enough "reset" of the B-cell compartment might allow the immune system to regenerate without the self-attacking clones that caused disease in the first place — potentially enabling patients to stop immunosuppressive drugs altogether rather than just controlling symptoms on them.

WHAT THE EARLY TRIAL DATA ACTUALLY SHOWS

The results published so far are genuinely striking for a field accustomed to incremental gains. The Erlangen group's first report, published in Nature Medicine in 2022, described five lupus patients who received anti-CD19 CAR-T cells; all achieved remission and were able to stop other lupus medications. A 2024 New England Journal of Medicine case series from the same group followed 15 patients across three diseases — 8 with severe SLE, 3 with inflammatory myositis, and 4 with systemic sclerosis. All 15 stopped immunosuppressive treatment after infusion, and at roughly 15 months of follow-up, all patients remained alive and in drug-free remission. Most recently, a phase 1/2a basket trial called CASTLE, published in Nature Medicine in 2026, enrolled 24 patients (10 SLE, 9 systemic sclerosis, 5 myositis): 9 of 10 SLE patients achieved formal disease-remission criteria, all 9 systemic sclerosis patients showed no disease progression, and 4 of 5 myositis patients hit major or moderate response criteria, with patients remaining off glucocorticoids and other immunosuppressants through 24 weeks. Independent groups have since reported smaller series in systemic sclerosis patients ineligible for stem cell transplant, with similar signals. These remain small, largely single-center, open-label studies without control arms — but the consistency of the remission signal across independent case series is unusual and is why the field has taken notice.

WHICH COMPANIES AND PROGRAMS ARE LEADING

Academic work in Germany kicked off the field, but biotech has moved quickly to commercialize it. Cabaletta Bio's CABA-201 has received FDA Fast Track designation for SLE/lupus nephritis, dermatomyositis, and systemic sclerosis. Kyverna Therapeutics has pursued KYV-101, receiving FDA Fast Track designation for lupus nephritis, and its related CAR-T candidate mivocabtagene autoleucel (miv-cel) reported striking phase 2 results in stiff person syndrome — a different, neurological autoimmune disease — with the company initiating a rolling FDA BLA submission in 2026, which would make it among the first CAR-T therapies approved for any autoimmune indication if successful. Cartesian Therapeutics is developing an RNA-based CAR-T candidate for myasthenia gravis and other autoimmune conditions using a different manufacturing approach intended to reduce the need for lymphodepleting chemotherapy. None of these programs has reached FDA approval for lupus, myositis, or systemic sclerosis specifically.

THE REAL RISKS AND UNKNOWNS

CAR-T therapy is not a simple infusion. Patients first undergo lymphodepleting chemotherapy (commonly fludarabine and cyclophosphamide) to clear existing immune cells and make room for the engineered T cells to expand — a regimen with its own toxicity, particularly in patients whose organs may already be compromised by autoimmune disease. The CAR-T infusion itself carries risk of cytokine release syndrome (CRS), a systemic inflammatory reaction that can range from mild fever to life-threatening organ dysfunction, and neurotoxicity (ICANS). In the published case series, CRS was common but mostly low-grade (in the 2024 NEJM series, 10 of 15 patients had grade 1 CRS and 1 had grade 2; the 2026 CASTLE trial reported no CRS above grade 2 and no ICANS at all), and serious infections occurred in a minority of patients. That said, the FDA has separately flagged broader concerns about CAR-T therapies in general, including a boxed warning tied to reports of secondary blood cancers in some cancer patients treated with CAR-T, and has said it is watching for unpredictable long-term toxicity — including effects on fertility — when these therapies are used in non-cancer, often younger patient populations who might otherwise have decades of life ahead. Every published autoimmune CAR-T study to date has followed patients for months to a few years at most; whether remissions hold for a decade, and whether any late-emerging risks appear, is simply not yet known.

REGULATORY STATUS AND WHAT WOULD NEED TO HAPPEN NEXT

As of August 2026, no CAR-T therapy has been approved by the FDA for any autoimmune disease. Several candidates hold Fast Track or RMAT (regenerative medicine advanced therapy) designations, which speed up FDA interactions but do not guarantee approval or shortcut safety review. The FDA has publicly signaled it intends to "carefully shepherd" this class into rheumatology, generally favoring initial approvals in patients with refractory disease who have failed multiple prior immunosuppressants, while acknowledging that standard may need to flex for severely ill patients facing irreversible organ damage. The agency has also pushed companies toward long-term follow-up studies modeled on those required for oncology CAR-T and gene therapies. For this approach to become an approved, routinely available treatment, sponsors will need larger randomized or controlled trials (most published data so far is uncontrolled), confirmation that remissions are durable over years rather than months, clearer identification of which patients benefit most, and continued reassurance on the secondary-malignancy and long-term-safety questions the FDA has raised.

Bottom Line

The early human data on CAR-T for autoimmune disease is among the most encouraging signals seen recently for patients with severe, treatment-refractory lupus, myositis, and systemic sclerosis — multiple independent case series and a growing basket trial have reported drug-free remission in the large majority of treated patients, something conventional immunosuppression rarely achieves. But this remains investigational medicine: sample sizes are small, follow-up is short, no CAR-T therapy is FDA-approved for any autoimmune indication, and the therapy carries real risks — from lymphodepleting chemotherapy to cytokine release syndrome to open questions about long-term safety, including secondary malignancy risk that the FDA has explicitly flagged. Patients and clinicians should treat this as a genuinely promising area to watch closely, pursued today only through clinical trials, not as an available or proven treatment.